TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
OTC · CRRTF · USD
Stock price, earnings
Quote as of Jun 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Crescita Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Crescita Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc.; and development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$1.29$0.00 (0.0%)
Healthy Extracts Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.22% below the high.
$0.00+$0.00 (+5.56%)
Univec, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.22% below the high.
CA$0.03CA$0.00 (0.0%)
Christina Lake Cannabis Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
$0.01+$0.00 (+20.48%)
CV Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
CA$0.09+CA$0.01 (+12.5%)
Delivra Health Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.29% below the high.
$0.00$0.00 (0.0%)
Ayr Wellness Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
